Coe Mary Ellen reported grant involving 206.4552 derivative units of Merck Co., Inc. at $145.31 for $30.0k on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Oct 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$30,000.01Shares × reported price
Shares traded
206.4552Phantom Stock
Price per share
$145.31Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
32,419.8658Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 1, 2026, 1:48 PM ET1-day reporting delay
Accession
0000310158-26-000230Code A · Transaction 232615
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MRK price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MRK · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +7.3%1w ago +7.3%1d ago +7.3%
Returns since7d −1%30d +4%90d180d1y

Footnotes in full

F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions.